Liability Related to the Sale of Future Royalties - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Nov. 30, 2022	Jun. 30, 2024	Dec. 31, 2022	Sep. 30, 2024	Sep. 30, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received				$ 0	$ 250,000
Milestone payment received				$ 50,000	$ 0
Royalty Pharma Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received			$ 250,000
Milestone payment receivable	$ 160,000
Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial	50,000
Milestone payment receivable upon FDA approval	50,000
Milestone payment receivable upon receipt of royalty payments	60,000
Royalty payment threshold	70,000
Milestone payment received		$ 50,000
Liability related to the sale of future royalties, interest rate				6.30%
Royalty Pharma Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Initial transaction price	$ 410,000